Who
David Malcom Rodman
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Mineralys Therapeutics; Exec Vice President and CMO, Nivalis Therapeutics.
In numbers
- Trades disclosed
- 381
- Buys
- 0
- Sells
- 49
- Bought
- $0
- Sold
- $34.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Jul 2016
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K2,170 at $16.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $59K2,170 at $27.09 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,170 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,170 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $35K2,170 at $16.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $59K2,170 at $27.09 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,423416 at $15.44 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K416 at $26.53 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —416 at $0.00 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —416 at $0.00 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,423416 at $15.44 | filing |
| 17 Jul 2026filed 20 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K416 at $26.53 | filing |
| 15 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $169K6,349 at $26.61 | filing |
| 15 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Sold | $169K6,349 at $26.61 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $36K3,542 at $10.20 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $59K4,167 at $14.25 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,8576,349 at $1.08 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,542 at $0.00 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,167 at $0.00 | filing |
| 13 Jul 2026filed 15 Jul 2026 | MLYS Mineralys Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,349 at $0.00 | filing |
News
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026MLYS · manilatimes.net · 22 Oct 2026Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel CoatsMLYS · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name David Malcom Rodman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.